ALFA Finder| Revenue growth | Q2 +195% YoY; inorganic build-out contributes; split undisclosed |
|---|---|
| Margins | EBITDA 26.8% Q2 vs 24.4% Q1; 39.6% Q2FY26 |
| Demand visibility | H1 IPD 11,040; OPD 78,643; 83%/82% of FY26 volumes |
Growth
Q2 revenue +11% QoQ, +195% YoY; PAT +24% QoQ, +129% YoY. H1 PAT +44% YoY; EBITDA +35% YoY.
Outlook
No explicit numeric guidance. Continued inorganic acquisitions; Dubai 49% balance stake pending; super-speciality upgrades.
Risks
Q2 EBITDA margin 26.8% vs 39.6% in Q2FY26 (-1281 bps). Employee costs +47% QoQ; goodwill up to ₹10,742L.
Investor Presentation filed with BSE, NSE: GKSL. Summary written with AI assistance from the document.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹156.37
- Market cap
- ₹1,233 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 64.9×Sector 54.5×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
Gujarat Kidney and Super Speciality Q2 FY27 Results: Net Profit ₹6.6 Cr, Up 127.6% YoY
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹38.1 Cr (+195.3% YoY) and net profit of ₹6.6 Cr (+127.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹6.6 Cr · +127.6% YoY
Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Annual Report
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.